Clover Health Investments (CLOV) investor relations material

Strategic vision and technology

• Focus on empowering physicians with AI-driven technology for earlier identification and management of chronic diseases, aiming to improve clinical outcomes and reduce costs.

• Clover Assistant leverages over 100 AI/ML models and integrates data from 100+ sources to generate personalized clinical insights at the point of care.

• Demonstrated improvements in chronic disease management, including earlier diagnoses and reduced hospitalizations for diabetes, CKD, CHF, and COPD.

• Achieved a 4.94 out of 5 HEDIS clinical quality score for plans with 2,000+ members and a 4.0 Star Rating for Payment Year 2026.

• Home Care program for high-acuity members has led to improved medical cost ratios over a three-year period.

Business model, financial performance, and growth outlook

• Differentiated by a wide PPO network, minimal risk delegation, and a preventive, tech-driven approach compared to traditional reactive models.

• Medicare Advantage membership grew 32% year-over-year, with sustained Adjusted EBITDA profitability of $43M year-to-date in 2025.

• 2025 guidance projects insurance revenue of $1.8B–$1.875B, Adjusted EBITDA of $50M–$70M, and Insurance BER of 88.5%–89.5%.

• Achieved FY24 profitability and expects to sustain profitability in FY25, positioning for accelerated growth and profitability in FY26.

• New revenue streams from Counterpart Health subsidiary, commercializing the Clover Assistant platform to other plans and providers.

Clinical outcomes and operational highlights

• Use of Clover Assistant correlated with earlier diagnosis and treatment of diabetes (by ~3 years) and CKD (by ~1.5 years), and lower reliance on insulin and hypoglycemia events.

• Significant reductions in all-cause hospitalizations and 30-day readmissions for CHF (18% and 25% lower) and COPD (15% and 18% lower) cohorts using Clover Assistant.

• Medication adherence improved by 5% on the day of a Clover Assistant visit and remained 3% higher after 90 days among previously non-adherent patients.

• 97% of members enrolled in PPO plans, with a wide network and technology-driven care model differentiating from traditional HMO-focused approaches.

• Cohort analysis shows maturing members drive incremental gross profit and lower medical cost ratios over time.